Skip to main content
Top
Published in: Molecular Diagnosis & Therapy 6/2015

Open Access 01-12-2015 | Original Research Article

Rapid Detection Method for the Four Most Common CHEK2 Mutations Based on Melting Profile Analysis

Authors: Pawel Borun, Kacper Salanowski, Dariusz Godlewski, Jaroslaw Walkowiak, Andrzej Plawski

Published in: Molecular Diagnosis & Therapy | Issue 6/2015

Login to get access

Abstract

Introduction

CHEK2 is a tumor suppressor gene, and the mutations affecting the functionality of the protein product increase cancer risk in various organs. The elevated risk, in a significant percentage of cases, is determined by the occurrence of one of the four most common mutations in the CHEK2 gene, including c.470T>C (p.I157T), c.444+1G>A (IVS2+1G>A), c.1100delC, and c.1037+1538_1224+328del5395 (del5395).

Methods

We have developed and validated a rapid and effective method for their detection based on high-resolution melting analysis and comparative-high-resolution melting, a novel approach enabling simultaneous detection of copy number variations. The analysis is performed in two polymerase chain reactions followed by melting analysis, without any additional reagents or handling other than that used in standard high-resolution melting.

Results

Validation of the method was conducted in a group of 103 patients with diagnosed breast cancer, a group of 240 unrelated patients with familial history of cancer associated with the CHEK2 gene mutations, and a 100-person control group. The results of the analyses for all three groups were fully consistent with the results from other methods.

Conclusion

The method we have developed improves the identification of the CHEK2 mutation carriers, reduces the cost of such analyses, as well as facilitates their implementation. Along with the increased efficiency, the method maintains accuracy and reliability comparable to other more labor-consuming techniques.
Appendix
Available only for authorised users
Literature
2.
go back to reference Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999;286(5449):2528–31.CrossRefPubMed Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999;286(5449):2528–31.CrossRefPubMed
3.
go back to reference Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3(5):421–9.CrossRefPubMed Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3(5):421–9.CrossRefPubMed
5.
go back to reference Brennan P, McKay J, Moore L, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, et al. Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study. Hum Mol Genet. 2007;16(15):1794–801. doi:10.1093/hmg/ddm127.CrossRefPubMed Brennan P, McKay J, Moore L, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, et al. Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study. Hum Mol Genet. 2007;16(15):1794–801. doi:10.​1093/​hmg/​ddm127.CrossRefPubMed
7.
8.
go back to reference Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131–5.PubMedCentralCrossRefPubMed Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131–5.PubMedCentralCrossRefPubMed
9.
go back to reference Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J, Debniak T, et al. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. J Med Genet. 2009;46(2):132–5. doi:10.1136/jmg.2008.061697.CrossRefPubMed Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J, Debniak T, et al. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. J Med Genet. 2009;46(2):132–5. doi:10.​1136/​jmg.​2008.​061697.CrossRefPubMed
10.
go back to reference Domagala P, Wokolorczyk D, Cybulski C, Huzarski T, Lubinski J, Domagala W. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;132(3):937–45. doi:10.1007/s10549-011-1635-7.CrossRefPubMed Domagala P, Wokolorczyk D, Cybulski C, Huzarski T, Lubinski J, Domagala W. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;132(3):937–45. doi:10.​1007/​s10549-011-1635-7.CrossRefPubMed
12.
go back to reference Bąk A, Janiszewska H, Junkiert-Czarnecka A, Heise M, Pilarska-Deltow M, Laskowski R, et al. A risk of breast cancer in women: carriers of constitutional CHEK2 gene mutations, originating from the North—Central Poland. Hereditary Cancer Clin Pract. 2014;12(1):10. doi: 10.1186/1897-4287-12-10.CrossRef Bąk A, Janiszewska H, Junkiert-Czarnecka A, Heise M, Pilarska-Deltow M, Laskowski R, et al. A risk of breast cancer in women: carriers of constitutional CHEK2 gene mutations, originating from the North—Central Poland. Hereditary Cancer Clin Pract. 2014;12(1):10. doi: 10.​1186/​1897-4287-12-10.CrossRef
14.
go back to reference Scharrer U, Skrzypczak-Zielinska M, Wituszynska W, Mierzejewski M, Krause K, Cybulski C, et al. A simple method of investigating mutations in CHEK2 by DHPLC: a study of the German populations of Saxony, Saxony-Anhalt, and Thuringia. Cancer Genet Cytogenet. 2010;199(1):48–52. doi:10.1016/j.cancergencyto.2009.11.015.CrossRefPubMed Scharrer U, Skrzypczak-Zielinska M, Wituszynska W, Mierzejewski M, Krause K, Cybulski C, et al. A simple method of investigating mutations in CHEK2 by DHPLC: a study of the German populations of Saxony, Saxony-Anhalt, and Thuringia. Cancer Genet Cytogenet. 2010;199(1):48–52. doi:10.​1016/​j.​cancergencyto.​2009.​11.​015.CrossRefPubMed
15.
go back to reference Siolek M, Cybulski C, Gasior-Perczak D, Kowalik A, Kozak-Klonowska B, Kowalska A, et al. CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer. 2015;137(3):548–52. doi:10.1002/ijc.29426.CrossRefPubMed Siolek M, Cybulski C, Gasior-Perczak D, Kowalik A, Kozak-Klonowska B, Kowalska A, et al. CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer. 2015;137(3):548–52. doi:10.​1002/​ijc.​29426.CrossRefPubMed
16.
go back to reference Kaczmarek-Rys M, Ziemnicka K, Hryhorowicz ST, Gorczak K, Hoppe-Golebiewska J, Skrzypczak-Zielinska M, et al. The c.470 T>C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population. Hereditary Cancer Clin Pract. 2015;13(1):8. doi:10.1186/s13053-015-0030-5.CrossRef Kaczmarek-Rys M, Ziemnicka K, Hryhorowicz ST, Gorczak K, Hoppe-Golebiewska J, Skrzypczak-Zielinska M, et al. The c.470 T>C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population. Hereditary Cancer Clin Pract. 2015;13(1):8. doi:10.​1186/​s13053-015-0030-5.CrossRef
18.
19.
go back to reference Kleibl Z, Havranek O, Hlavata I, Novotny J, Sevcik J, Pohlreich P, et al. The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer. 2009;45(4):618–24. doi:10.1016/j.ejca.2008.09.022.CrossRefPubMed Kleibl Z, Havranek O, Hlavata I, Novotny J, Sevcik J, Pohlreich P, et al. The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer. 2009;45(4):618–24. doi:10.​1016/​j.​ejca.​2008.​09.​022.CrossRefPubMed
21.
go back to reference Borun P, Kubaszewski L, Banasiewicz T, Walkowiak J, Skrzypczak-Zielinska M, Kaczmarek-Rys M, et al. Comparative-high resolution melting: a novel method of simultaneous screening for small mutations and copy number variations. Hum Genet. 2014;133(5):535–45. doi:10.1007/s00439-013-1393-1.PubMedCentralCrossRefPubMed Borun P, Kubaszewski L, Banasiewicz T, Walkowiak J, Skrzypczak-Zielinska M, Kaczmarek-Rys M, et al. Comparative-high resolution melting: a novel method of simultaneous screening for small mutations and copy number variations. Hum Genet. 2014;133(5):535–45. doi:10.​1007/​s00439-013-1393-1.PubMedCentralCrossRefPubMed
22.
go back to reference Cybulski C, Huzarski T, Gorski B, Masojc B, Mierzejewski M, Debniak T, et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res. 2004;64(8):2677–9.CrossRefPubMed Cybulski C, Huzarski T, Gorski B, Masojc B, Mierzejewski M, Debniak T, et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res. 2004;64(8):2677–9.CrossRefPubMed
Metadata
Title
Rapid Detection Method for the Four Most Common CHEK2 Mutations Based on Melting Profile Analysis
Authors
Pawel Borun
Kacper Salanowski
Dariusz Godlewski
Jaroslaw Walkowiak
Andrzej Plawski
Publication date
01-12-2015
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 6/2015
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-015-0171-2

Other articles of this Issue 6/2015

Molecular Diagnosis & Therapy 6/2015 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine